CMPS vs. ARDX, ZYME, LENZ, OCS, ORIC, PRAX, COGT, CMRX, CDMO, and AVXL
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Oculis (OCS), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs. Its Competitors
Ardelyx (NASDAQ:ARDX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.
Ardelyx has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500.
58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by insiders. Comparatively, 3.9% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Ardelyx had 4 more articles in the media than COMPASS Pathways. MarketBeat recorded 7 mentions for Ardelyx and 3 mentions for COMPASS Pathways. Ardelyx's average media sentiment score of 0.38 beat COMPASS Pathways' score of 0.00 indicating that Ardelyx is being referred to more favorably in the media.
COMPASS Pathways has a net margin of 0.00% compared to Ardelyx's net margin of -14.86%. Ardelyx's return on equity of -34.45% beat COMPASS Pathways' return on equity.
Ardelyx has higher revenue and earnings than COMPASS Pathways. Ardelyx is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
Ardelyx presently has a consensus price target of $10.89, indicating a potential upside of 153.52%. COMPASS Pathways has a consensus price target of $17.00, indicating a potential upside of 421.63%. Given COMPASS Pathways' higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Ardelyx.
Summary
Ardelyx beats COMPASS Pathways on 12 of the 16 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 7/5/2025 by MarketBeat.com Staff
